Long-term cardiac safety and survival outcomes of neoadjuvant pegylated liposomal doxorubicin in elderly patients or prone to cardiotoxicity and triple negative breast cancer. Final results of the multicentre phase II CAPRICE study

The CAPRICE trial evaluated neoadjuvant pegylated liposomal doxorubicin in elderly patients or in those with other cardiovascular risk factors in whom conventional doxorubicin was contraindicated. This article reports the secondary study objectives: 5-year cardiac safety, disease-free survival, overall survival, and breast cancer specific survival.